Additional file 2 of Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study

Additional file 2: Table S1. The formula used to calculate R2 and F statistic between exposure and outcome; Table S2. Summary statistics of the anxiety disorders; Table S3–S12. Mendelian Randomization estimation for Amino acid(Table S3); Carbohydrate (Table S4); Co-factor or vitamin(Table S5);Energy(Table S6); Lipid(Table S7); Nucleotide (Table S8); Peptide (Table S9); Xenobiotic(Table S10);X(unknow metabolites) (Table S11);known metabolites (Table S12) on the risk of anxiety disorders; Table S13. The characteristics of SNPs and their genetic associations with known metabolites and the anxiety disorders; Table S15. The reverse MR analysis of 1-linoleoylglycerophosphoethanolamine and anxiety disorders using various methods; Table S16. Association of 1linoleoylglycerophosphoethanolamine and additional anxiety disorders GWAS using various methods; Table S14, S17–S21. Summary statistics for the associations of the five metabolites (passed all the sensitivity analyses)-associated SNPs with these exposures and the anxiety disorders from MRC-IEU Consortium; Table S22. Metabolic Pathway Associated with self-reported anxiety; Table S23. Clinical characteristics of participants involved in the study; Table S24. Characteristics of the KORA population related to antihypertensives and lipid-lowering drugs; Table S25. Characteristics and patterns of anti-hyperglycemic treatment of participants with self-reported type 2 diabetes in the KORA F4 study.